Roman J. Fleck
Directeur Général chez Janpix Holdings, Inc.
Profil
Roman J.
Fleck is currently the Chief Executive Officer at Janpix Holdings, Inc. and Chairman at VaxNewMo LLC.
Previously, he was a Director at Versartis, Inc. and Diartis Pharmaceuticals, Inc. He also served as a Director-Supervisory Board at GlycoVaxyn AG and as a Principal at Index Ventures SA from 2009 to 2014.
Fleck holds a doctorate from the Massachusetts Institute of Technology and an MBA from New York University.
Postes actifs de Roman J. Fleck
| Sociétés | Poste | Début |
|---|---|---|
Janpix Holdings, Inc.
 Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Directeur Général | 01/09/2014 |
VaxNewMo LLC
 VaxNewMo LLC BiotechnologyHealth Technology VaxNewMo LLC is an early-stage biotechnology company based in St. Louis, MO. The company is developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. The company is breaking through the barrier of limited range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation. The company was founded by Mario Feldman, Christian Harding, and Christine Szymanski. Michael Timothy Cooke has been the CEO of the company since 2022. | Président | - |
Anciens postes connus de Roman J. Fleck
| Sociétés | Poste | Fin |
|---|---|---|
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Private Equity Investor | 31/08/2014 |
Diartis Pharmaceuticals, Inc.
 Diartis Pharmaceuticals, Inc. BiotechnologyHealth Technology Diartis Pharmaceuticals, Inc. developed therapeutic proteins for the treatment of metabolic disorders. The company was founded by Jeffrey L. Clearland in December 2010 and headquartered in Redwood City, CA. | Directeur/Membre du Conseil | - |
GlycoVaxyn AG
 GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Directeur/Membre du Conseil | - |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Directeur/Membre du Conseil | - |
Formation de Roman J. Fleck
| Massachusetts Institute of Technology | Doctorate Degree |
| New York University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Finance |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
Diartis Pharmaceuticals, Inc.
Diartis Pharmaceuticals, Inc. BiotechnologyHealth Technology Diartis Pharmaceuticals, Inc. developed therapeutic proteins for the treatment of metabolic disorders. The company was founded by Jeffrey L. Clearland in December 2010 and headquartered in Redwood City, CA. | Health Technology |
Janpix Holdings, Inc.
Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Commercial Services |
VaxNewMo LLC
VaxNewMo LLC BiotechnologyHealth Technology VaxNewMo LLC is an early-stage biotechnology company based in St. Louis, MO. The company is developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. The company is breaking through the barrier of limited range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation. The company was founded by Mario Feldman, Christian Harding, and Christine Szymanski. Michael Timothy Cooke has been the CEO of the company since 2022. | Health Technology |
